恩格列净作为利格列汀与二甲双胍控制不佳的2型糖尿病患者的附加治疗:一项24周随机双盲平行组试验
本研究纳入二甲双胍稳定剂量下HbA1c≥8.0%且≤10.5%的2型糖尿病患者,先接受开放标签利格列汀5 mg治疗16周,随后将HbA1c≥7.0且≤10.5%者随机分配至恩格列净10 mg、25 mg或安慰剂组治疗24周。结果显示恩格列净10 mg和25 mg较安慰剂显著降低HbA1c,空腹血糖和体重亦显著降低,不良事件报告率低于安慰剂组。
要点
- 恩格列净10 mg和25 mg较安慰剂显著降低HbA1c,调整后平均差异分别为-0.79%和-0.70%。
- 恩格列净两剂量组空腹血糖和体重较安慰剂均显著降低(P<0.001)。
- 安慰剂组不良事件报告率高于恩格列净10 mg和25 mg组(68.2% vs 55.4%和51.8%)。
核心结论
- 恩格列净作为利格列汀5 mg与二甲双胍的附加治疗,治疗24周较安慰剂改善血糖控制和体重,且耐受性良好。
研究设计与样本
- 随机、双盲、双模拟、平行组试验:患者先接受开放标签利格列汀5 mg(n=606)治疗16周,随后HbA1c≥7.0且≤10.5%者随机分配至恩格列净10 mg(n=112)、恩格列净25 mg(n=111)或安慰剂(n=110)治疗24周,所有患者继续二甲双胍和利格列汀5 mg治疗。
- 主要终点为双盲治疗24周后HbA1c较基线的变化。
主要发现
- 第24周时,恩格列净10 mg和25 mg较安慰剂显著降低HbA1c(平均基线7.96-7.97% [63-64 mmol/mol]),调整后平均差异分别为-0.79%(95% CI ‒1.02, ‒0.55)(-8.63 mmol/mol [‒11.20, ‒6.07 mmol/mol])和-0.70%(95% CI ‒0.93, ‒0.46)(-7.61 mmol/mol [‒10.18, ‒5.05 mmol/mol]),均P<0.001。
- 恩格列净两剂量组空腹血糖和体重较安慰剂均显著降低(所有比较P<0.001)。
- 双盲治疗期间,安慰剂组、恩格列净10 mg组和25 mg组报告不良事件的患者比例分别为68.2%、55.4%和51.8%。
关键数值与推荐
- 入选时HbA1c≥8.0%且≤10.5%(≥64且≤91 mmol/mol),且接受稳定剂量二甲双胍治疗。
- 开放标签利格列汀5 mg治疗16周后,HbA1c≥7.0且≤10.5%(≥53且≤91 mmol/mol)者进入随机化阶段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of empagliflozin versus placebo as add-on therapy in patients with type 2 diabetes and inadequate glycemic control with linagliptin and metformin. RESEARCH DESIGN AND METHODS: Patients with HbA1c ≥8.0% and ≤10.5% (≥64 and ≤91 mmol/mol) while receiving stable-dose metformin received open-label linagliptin 5 mg (n = 606) for 16 weeks. Subsequently, those with HbA1c ≥7.0 and ≤10.5% (≥53 and ≤91 mmol/mol) were randomized to receive double-blind, double-dummy treatment with empagliflozin 10 mg (n = 112), empagliflozin 25 mg (n = 111), or placebo (n = 110) for 24 weeks; all patients continued treatment with metformin and linagliptin 5 mg. The primary end point was the change from baseline in HbA1c after 24 weeks of double-blind treatment. RESULTS: At week 24, empagliflozin significantly reduced HbA1c (mean baseline 7.96-7.97% [63-64 mmol/mol]) versus placebo; the adjusted mean differences in the change from baseline with empagliflozin 10 and 25 mg versus placebo were -0.79% (95% CI ‒1.02, ‒0.55) (-8.63 mmol/mol [‒11.20, ‒6.07 mmol/mol]) and -0.70% (95% CI ‒0.93, ‒0.46) (-7.61 mmol/mol [‒10.18, ‒5.05 mmol/mol]), respectively (both P < 0.001). Fasting plasma glucose and weight were significantly reduced in both empagliflozin groups versus placebo (P < 0.001 for all comparisons). More patients receiving placebo than empagliflozin 10 and 25 mg reported adverse events during double-blind treatment (68.2%, 55.4%, and 51.8%, respectively). CONCLUSIONS: Empagliflozin treatment for 24 weeks improved glycemic control and weight versus placebo as an add-on to linagliptin 5 mg and metformin and was well tolerated.
引用
- Søfteland E, Meier JJ, Vangen B, et al. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2016. PMID: 27913576. doi:10.2337/dc16-1347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。